Connect your AI

Integra LifeSciences IART Total Equity

Total Equity at other companies

Becton, Dickinson and CompanyBDX

$24.13B-4.4%

AxogenAXGN

$244.81M+132%

Globus MedicalGMED

$4.73B+15.8%

AbbVieABBV

-$6.66B-569%

MedtronicMDT

$49.46B+3.0%

STERISSTE

$7.18B+8.8%

Other financials

Income statement

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total assets$3.6B-11.7%

Cash flow

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

Market cap$1.38B-56.8%

Enterprise value$3.12B-26.7%

P/S0.8×-1.1×

Profitability

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Integra LifeSciences's total equity?: Integra LifeSciences (IART) reported total equity of $1.04B in Q1 2026.
How has Integra LifeSciences's total equity changed year-over-year?: Integra LifeSciences's total equity decreased by 31.6% year-over-year, from $1.52B to $1.04B.
What is the long-term trend for Integra LifeSciences's total equity?: Over 5 years (2020 to 2025), Integra LifeSciences's total equity has grown at a -7.2% compound annual growth rate (CAGR), from $1.51B to $1.04B.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.